Orforglipron in type 2 diabetes mellitus and obesity: an overview
Orforglipron is a promising treatment option for T2DM and overweight or obesity, in terms of glucose control and weight loss. The increased frequency of adverse events, particularly in those receiving high doses and after rapid-dose escalation, requires caution before widespread use.
Authors
- Djordje S. Popovic (ORCID: https://orcid.org/0000-0002-2763-1326)
- Theodoros Panou (ORCID: https://orcid.org/0009-0008-6564-0267)
- Νικόλαος Παπάνας (ORCID: https://orcid.org/0000-0002-7320-785X)
- Evanthia Gouveri (ORCID: https://orcid.org/0000-0002-7410-4326)
Institutions
- Democritus University of Thrace (GR)
- University of Novi Sad (RS)
- Klinički centar Vojvodine (RS)
- Oncology Institute of Vojvodina (RS)
Publication Details
- Journal
- Expert Review of Clinical Pharmacology
- Published
- 2025-11-02
- DOI
- https://doi.org/10.1080/17512433.2025.2594493
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29